Potential Link Found Between Immune Reactions & Tardive Dyskinesia
Researchers proposed a hypothesis linking dysfunctions in the striatum and the dorsal diencephalic connection system (DDCS) to classic tardive dyskinesia (TD).
Read More
Dissemination (Spotlight)
RECIP 1.0’s Prognostic Value in Biochemically Recurrent Prostate Cancer Imaging
The following is a summary of “Prognostic utility of RECIP 1.0 with manual and AI-based...
Read More
Mortality Risk Comparable With Continuous Versus Intermittent ADT for Prostate Cancer
An analysis of 12 clinical trials shows no difference in mortality risk with continuous versus intermittent androgen deprivation therapy for prostate cancer.
Read More
Caring for Patients With Tardive Dyskinesia Can Present Challenges
Healthcare professionals should consider a complete therapeutic approach that includes the input of caregivers assisting patents with TD.
Read More
In Clinical Trial Setting, Survival Is Similar for Black & White Patients With Prostate Cancer
Both Black and White patients with metastatic castration-sensitive prostate cancer (mCSPC) showed similar progression-free survival and overall survival in a clinical trial setting.
Read More
Metastatic Prostate Cancer With BRCA Deficiency has a Poor Prognosis & a Unique Genetic Profile
The following is a summary of “BRCA-deficient metastatic prostate cancer has an adverse...
Read More
Functional MRI Identifies Changes in Cerebral Regional Homogeneity Among Patients With TD
Resting-state functional MRI results show that patients with schizophrenia and tardive dyskinesia have altered cerebral regional homogeneity.
Read More
Telehealth Complements In-Person Visits for Tardive Dyskinesia
Physicians typically address movement disorders, such as tardive dyskinesia, during in-person examinations; however, a recent study shows that telehealth visits can be a part of treatment plans.
Read More
VMAT2 Inhibitors May Improve Well-Being in Addition to TD Symptoms
Patients with tardive dyskinesia being treated with vesicular monoamine transporter 2 inhibitors may see improvement in well-being along with TD symptoms.
Read More
Biomarkers May Aid Therapeutic Interventions to Ease Impact of Schizophrenia With TD
Between 20% and 30% of patients with schizophrenia (SCZ)—and up to 50% patients with SCZ older than 50—develop tardive dyskinesia (TD), according to a study published in Genes & Genomics.
Read More
Biomarker Testing “Essential” to Ensure Appropriate Treatment in NSCLC
An uptick in biomarker testing for non-small cell lung cancer (NSCLC) over the past decade indicates an ongoing trend toward personalization of treatment choices.
Read More
In Advanced NSCLC, Treatment Based on Biomarker Testing Improves Survival
First-line treatment that aligns with the results of biomarker testing and treatment guidelines is linked with better survival outcomes in patients with advanced or metastatic NSCLC.
Read More
Timely Biomarker Testing in NSCLC Informs Treatment Selection
Biomarker testing in non-small cell lung cancer informs therapeutic decisions at all stages of...
Read More
Biomarker Testing of Patients With NSCLC Can Aid Survival
Comprehensive biomarker testing of patients with non-small lung cancer (NSCLC) is a critical part...
Read More
Apalutamide Linked With Faster Time to PSA90 Than Abiraterone Acetate
In metastatic castration-sensitive prostate cancer, patients on apalutamide were 53% more likely...
Read More
Q&A: “Initiate Open Conversations” to Manage Financial Toxicity in Prostate Cancer
Routine conversations about costs can address the financial toxicity associated with new...
Read More
Assessing Liquid Biopsy Alongside Tissue Testing in NSCLC Genotyping
Biomarker testing is crucial for managing non-small cell lung cancer (NSCLC), with plasma-based...
Read More
Patients & Physicians Want NSCLC Biomarker Education Materials
Researchers conducted a study to investigate the experiences of patients and clinicians regarding...
Read More
Comprehensive mNSCLC Biomarker Testing in Large Community Practice Feasible & Successful
A study aimed to enhance comprehensive biomarker testing for patients with metastatic...
Read More
For Metastatic NSCLC, Biomarker Testing Rates Up, But Genotyping Gaps Persist
A study aimed to analyze changes in biomarker testing among patients with metastatic non-small...
Read More